CARIS LIFE SCIENCES, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $-68.1M | $-281.9M | $-341.4M |
| Depreciation & Amortization | $22.6M | $48.9M | $49.0M |
| Depreciation | — | — | — |
| Amortization | — | — | — |
| Stock-Based Compensation | $70.0M | $18.6M | $15.2M |
| Net Cash from Operating Activities | $83.2M | $-245.2M | $-276.1M |
| Investing Activities | |||
| Capital Expenditures | $16.3M | $8.4M | $22.3M |
| Business Acquisitions | — | — | — |
| Net Cash from Investing Activities | $-16.3M | $52.9M | $214.8M |
| Financing Activities | |||
| Dividends Paid | — | — | — |
| Stock Repurchases | $113.0K | $0 | $0 |
| Net Cash from Financing Activities | $665.0M | $200.3M | $10.1M |
| Net Change in Cash | $732.0M | $8.0M | $-51.1M |
| Free Cash Flow | $66.9M | $-253.6M | $-298.4M |